Literature DB >> 21735057

Malignant lymphomas and autoimmunity-a single center experience from Hungary.

László Váróczy1, Edit Páyer, Zsuzsanna Kádár, Lajos Gergely, Zsófia Miltényi, Ferenc Magyari, Péter Szodoray, Arpád Illés.   

Abstract

Autoimmune diseases and malignant lymphomas have numerous similarities in their etiology and pathogenesis. Patients with autoimmune disorders have increased risk to develop non-Hodgkin's lymphomas, yet little is known about the occurrence of autoimmune features within lymphoma patients. Our aim was to examine the prevalence of autoimmune diseases among patients with non-Hodgkin's (NHL) and Hodgkin's lymphoma (HL). We reviewed 352 patients' charts with malignant lymphomas to assess the rate of associated autoimmune diseases. Of 231 NHL patients, 30 (12.9%) had autoimmune disorders, while there were 11 patients who suffered from more than one disease entity. It was Sjögren's syndrome that occurred in the largest number (eight cases), other frequent entities were undifferentiated connective tissue disease (seven), thyroiditis (six), rheumatoid arthritis (four), and systemic vasculitis (four). The female/male ratio was significantly different between patients with or without autoimmune diseases, while no other clinical features differed significantly between the two groups. Ten patients (33.3%) were initially diagnosed with lymphoma, 13 (43.3%) of them had already been diagnosed with autoimmune disease at the time of lymphoma occurrence. Six patients (20%) with previously diagnosed immunological disorder developed new autoimmune condition after the treatment of lymphoma. Lymphoma and autoimmune disease occurred simultaneously in one patient. Among the 121 HL patients, 14 (11.5%) had associated autoimmune disease. Ten patients developed thyroiditis after the lymphoma treatment, two had immune thrombocytopenia, and one had autoimmune hemolytic anemia. One female patient was diagnosed with systemic sclerosis 10 years before the onset of HL. Our results highlight that an increased risk for the development of autoimmune diseases should be considered in patients both with NHL and HL.

Entities:  

Mesh:

Year:  2011        PMID: 21735057     DOI: 10.1007/s10067-011-1807-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  25 in total

1.  Autoimmunity and lymphoma: tribulations of B cells.

Authors:  I R Mackay; N R Rose
Journal:  Nat Immunol       Date:  2001-09       Impact factor: 25.606

2.  Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype.

Authors:  Karin Ekström Smedby; Henrik Hjalgrim; Johan Askling; Ellen T Chang; Henrik Gregersen; Anna Porwit-MacDonald; Christer Sundström; Måns Akerman; Mads Melbye; Bengt Glimelius; Hans-Olov Adami
Journal:  J Natl Cancer Inst       Date:  2006-01-04       Impact factor: 13.506

3.  Immunoregulatory T cells in the peripheral blood of patients with Hodgkin's lymphoma.

Authors:  Sándor Baráth; Magdolna Aleksza; Katalin Keresztes; Judit Tóth; Sándor Sipka; Gyula Szegedi; Arpád Illés
Journal:  Acta Haematol       Date:  2006       Impact factor: 2.195

Review 4.  B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling.

Authors:  Fabienne Mackay; Pablo A Silveira; Robert Brink
Journal:  Curr Opin Immunol       Date:  2007-04-12       Impact factor: 7.486

Review 5.  Hodgkin's lymphoma in systemic lupus erythematosus.

Authors:  S Bernatsky; R Ramsey-Goldman; D Isenberg; A Rahman; M A Dooley; J Sibley; J-F Boivin; L Joseph; J Armitage; A Zoma; A Clarke
Journal:  Rheumatology (Oxford)       Date:  2007-01-25       Impact factor: 7.580

6.  Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Authors:  J Askling; C M Fored; E Baecklund; L Brandt; C Backlin; A Ekbom; C Sundström; L Bertilsson; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog; N Feltelius
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

7.  Antibodies against extractable nuclear antigen in non-Hodgkin lymphoma patients.

Authors:  L Gergely; A Dankó; I Csípõ; L Váróczy; S Sipka; M Zeher; A Illés
Journal:  Scand J Immunol       Date:  2005-04       Impact factor: 3.487

Review 8.  Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients.

Authors:  Michael Voulgarelis; Fotini N Skopouli
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

9.  Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus.

Authors:  Lena Björnådal; Björn Löfström; Li Yin; Ingrid E Lundberg; Anders Ekbom
Journal:  Scand J Rheumatol       Date:  2002       Impact factor: 3.641

Review 10.  B-cell lymphoproliferation in chronic inflammatory rheumatic diseases.

Authors:  Arne Hansen; Peter E Lipsky; Thomas Dörner
Journal:  Nat Clin Pract Rheumatol       Date:  2007-10
View more
  2 in total

1.  Expression of Sirt1 and FoxP3 in classical Hodgkin lymphoma and tumor infiltrating lymphocytes: Implications for immune dysregulation, prognosis and potential therapeutic targeting.

Authors:  Andrés E Quesada; Binara Assylbekova; Christine E Jabcuga; Rongzhen Zhang; Michael Covinsky; Adan Rios; Nghia D Nguyen; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 2.  Autoimmune Complications in Hematologic Neoplasms.

Authors:  Wilma Barcellini; Juri Alessandro Giannotta; Bruno Fattizzo
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.